We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affymetrix, Reveal Biosciences Partner
News

Affymetrix, Reveal Biosciences Partner

Affymetrix, Reveal Biosciences Partner
News

Affymetrix, Reveal Biosciences Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix, Reveal Biosciences Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affymetrix Inc. and Reveal Biosciences LLC have announced a partnership agreement through which Reveal will use Affymetrix ViewRNA® ISH products for tissue samples to provide RNA in situ hybridization (ISH) staining, imaging, and quantification services using the company’s proprietary image analysis software, ImageDx™.

“RNA in situ hybridization is fast becoming the method of choice for researchers wanting to validate established and novel biomarkers for translational and clinical research,” said Guy Afseth, marketing director for Affymetrix’ oncology portfolio. With Affymetrix’ ViewRNA ISH portfolio for tissue samples, researchers can rapidly design assays for virtually any mRNA transcript or long noncoding RNA in any tissue type. ViewRNA assays utilize branched DNA signal amplification technology to achieve unparalleled sensitivity and specificity, enabling the visualization of targets at the single-molecule level within the context of the tissue morphology.

“We are thrilled to partner with Affymetrix to provide high-quality services using ViewRNA products. Our scientific expertise, combined with high-resolution imaging and our proprietary image analysis software, ImageDx™, form a powerful platform for the localization and quantification of mRNA in tissue samples,” said Dr. Claire Weston, CEO and founder of Reveal Biosciences. “This highly sensitive technology is changing the face of mRNA biomarker screening and analysis for translational research and diagnostics.”

Advertisement